An experimental drug called selinexor made by Karyopharm Therapeutics (KPTI) hastened the death of patients with an advanced form of leukemia, but the company never publicly disclosed the negative outcome observed in the randomized clinical trial.

Karyopharm stopped the selinexor clinical trial prematurely in 2017 but the higher death rate was not revealed until Friday, when the Food and Drug Administration disclosed it as part of a skeptical review that could stop the drug from reaching the market.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy